Series: Landmark Trials in Endocrinology & Metabolism | Study #26
Category: Diabetes Prevention | Design: Multicentre, double-blind, randomised controlled trial | n: 3,234 | Follow-up: 2.8 years (mean)
📋 Summary
Authors: Knowler WC et al., for the Diabetes Prevention Program Research Group
Journal: N Engl J Med 2002;346:393–403 | DOI: 10.1056/NEJMoa012512
The Diabetes Prevention Program enrolled 3,234 non-diabetic adults with elevated fasting and post-load plasma glucose concentrations, a mean age of 51 years, and a mean BMI of 34.0 kg/m², of whom 68% were women and 45% were from minority groups. Participants were randomly assigned to placebo, metformin 850 mg twice daily, or an intensive lifestyle-modification programme with goals of at least 7% weight loss and at least 150 minutes of physical activity per week. After a mean follow-up of 2.8 years, the incidence of type 2 diabetes was 11.0 cases per 100 person-years in the placebo group, 7.8 in the metformin group, and 4.8 in the lifestyle group. The lifestyle intervention reduced diabetes incidence by 58% (95% CI 48 to 66%; p<0.001) and metformin by 31% (17 to 43%; p<0.001) compared with placebo. The lifestyle intervention was significantly more effective than metformin (p<0.001). To prevent one case of diabetes over three years, 6.9 persons needed to participate in the lifestyle programme and 13.9 needed to receive metformin. Subgroup analyses showed that the lifestyle benefit was consistent across ethnic groups, sexes, and ages, while the metformin benefit was greatest in younger participants and those with higher BMI, particularly those closest to a diabetes diagnosis by glucose criteria.
📊 Key Findings
| Group | Diabetes incidence (per 100 PY) | Reduction vs placebo | NNT (3 years) |
|---|---|---|---|
| Placebo | 11.0 | — | — |
| Metformin 850 mg BD | 7.8 | 31% (17–43%) · p<0.001 | 13.9 |
| Intensive lifestyle | 4.8 | 58% (48–66%) · p<0.001 | 6.9 |
| Lifestyle vs metformin superiority | p<0.001 (lifestyle significantly more effective) | ||
💬 Expert Commentary
The Diabetes Prevention Program is the pivotal randomised evidence base for all national diabetes prevention programmes. Its significance extends far beyond the immediate clinical finding for several reasons. The 58% reduction in diabetes incidence with lifestyle intervention, achieving a NNT of approximately 7 over 2.8 years, is among the most favourable NNTs reported for any preventive intervention in a chronic disease setting and justifies the substantial resource investment required for structured lifestyle programmes. The magnitude of benefit was consistent across ethnic subgroups, including African American, Hispanic, Asian American, and Native American participants, who are disproportionately at risk of type 2 diabetes in the United States — a finding that established the generalisability of lifestyle intervention beyond the predominantly white populations studied in earlier European prevention trials.
The metformin arm provides a pharmacological reference point that has remained clinically relevant for decades. A 31% reduction in diabetes incidence with metformin at low cost and with a favourable safety profile established a strong evidence base for metformin as a preventive agent in high-risk individuals who are unable to achieve the lifestyle intervention targets, or in those at highest short-term risk of diabetes progression. The finding that metformin was most effective in younger, heavier participants with the highest fasting glucose values helped refine the target population for pharmacological prevention. The DPP was followed by the DPPOS (Study #28 in this series), which tracked participants for 10 years and demonstrated that the cumulative incidence of diabetes remained lowest in the former lifestyle group, with a 34% reduction maintained over a decade, establishing that the benefit of early lifestyle intervention extends well beyond the active intervention period.
Limitations: The mean follow-up of 2.8 years does not address long-term maintenance of benefit (see DPPOS). The lifestyle intervention was resource-intensive, involving 16 individual sessions in the first year, which may limit reproducibility in healthcare systems with limited prevention infrastructure. The study was funded by the NIH and CDC.
🔑 BOTTOM LINE
The Diabetes Prevention Program demonstrated that intensive lifestyle intervention reduces the incidence of type 2 diabetes by 58% in high-risk adults with a NNT of 6.9 over 2.8 years, significantly exceeding the 31% reduction achieved by metformin, establishing structured lifestyle modification as the most effective preventive strategy in pre-diabetes and forming the evidence base for national diabetes prevention programmes worldwide.
⭐ Clinical Impact Rating: ●●●●● Practice-defining
